Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) has a market capitalization of $824.00 Million (CN¥5.63 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #10069 globally and #2875 in its home market, demonstrating a 3.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's stock price CN¥8.01 by its total outstanding shares 703000000 (703.00 Million). Analyse 688505 cash flow metrics to see how efficiently the company converts income to cash.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap History: 2020 to 2026
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $1.72 Billion to $824.00 Million (-22.49% CAGR).
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.25x
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap is 1.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.72 Billion | $833.80 Million | $164.66 Million | 2.07x | 10.46x |
| 2021 | $1.41 Billion | $1.14 Billion | $213.30 Million | 1.24x | 6.60x |
| 2022 | $840.14 Million | $1.03 Billion | $138.00 Million | 0.81x | 6.09x |
| 2023 | $936.27 Million | $850.73 Million | $108.63 Million | 1.10x | 8.62x |
| 2024 | $789.02 Million | $709.40 Million | $39.73 Million | 1.11x | 19.86x |
| 2025 | $853.83 Million | $685.80 Million | -$157.44 Million | 1.25x | N/A |
Competitor Companies of 688505 by Market Capitalization
Companies near Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap moved from $1.72 Billion to $ 824.00 Million, with a yearly change of -22.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥824.00 Million | -3.49% |
| 2025 | CN¥853.83 Million | +8.21% |
| 2024 | CN¥789.02 Million | -15.73% |
| 2023 | CN¥936.27 Million | +11.44% |
| 2022 | CN¥840.14 Million | -40.36% |
| 2021 | CN¥1.41 Billion | -18.23% |
| 2020 | CN¥1.72 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $824.00 Million USD |
| MoneyControl | $824.00 Million USD |
| MarketWatch | $824.00 Million USD |
| marketcap.company | $824.00 Million USD |
| Reuters | $824.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more